Longeveron Inc (LGVN)

$0.94 -0.04 (-3.73%)
Market Cap 22.72M
Revenue (ttm) 1.20M
Net Income (ttm) -22.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,891.67%
Debt to Equity Ratio 0.03
Volume 171,300
Avg Vol 6,891,436
Day's Range N/A - N/A
Shares Out 23.27M
Stochastic %K 6%
Beta -0.18
Analysts Strong Sell
Price Target $6.61

Company Profile

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 470 2550
Address:
Life Science & Technology Park, Suite 520 1951 NW 7th Avenue, Miami, United States
smojo2
smojo2 Apr. 23 at 2:11 PM
$LGVN Man i was excited for to have a golden cross but its been bad. Need some volume and buying
0 · Reply
Carolinastokes1
Carolinastokes1 Apr. 21 at 4:15 PM
$LGVN has anyone heard they are releasing 30 million shares?
0 · Reply
tommiemac
tommiemac Apr. 21 at 4:10 PM
$LGVN bought in here like what this company is doing
0 · Reply
tommiemac
tommiemac Apr. 21 at 4:06 PM
$LGVN what does it take to buy on Webull
0 · Reply
Kingdaley
Kingdaley Apr. 20 at 6:46 PM
$LGVN going up from here
0 · Reply
Kingdaley
Kingdaley Apr. 20 at 6:43 PM
$LGVN golden cross baby
0 · Reply
seven7s
seven7s Apr. 16 at 3:59 AM
$LGVN $10K putting in this tmrw
0 · Reply
janlukas
janlukas Apr. 15 at 9:20 PM
$LGVN 10 days above a dollar, almost there, and then a crazy rush to $100. We have a unique pipeline.
0 · Reply
DoiRTN
DoiRTN Apr. 15 at 2:08 PM
$LGVN Why so silent?
0 · Reply
milk25
milk25 Apr. 14 at 11:35 PM
$LGVN are we at nasdaq compliance now
1 · Reply
Latest News on LGVN
Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

Apr 8, 2026, 9:15 AM EDT - 17 days ago

Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

Mar 17, 2026, 4:05 PM EDT - 5 weeks ago

Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

Longeveron Braces For Q4 Results Following Recent Funding Boost

Mar 17, 2026, 3:16 PM EDT - 5 weeks ago

Longeveron Braces For Q4 Results Following Recent Funding Boost

Longeveron Announces Closing of Private Placement of up to $30 Million

Mar 11, 2026, 4:05 PM EDT - 6 weeks ago

Longeveron Announces Closing of Private Placement of up to $30 Million

Longeveron (LGVN) Shares Surge On $30 Million Private Placement Deal

Mar 10, 2026, 3:58 PM EDT - 6 weeks ago

Longeveron (LGVN) Shares Surge On $30 Million Private Placement Deal

Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell

Feb 25, 2026, 11:05 AM EST - 2 months ago

Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell

Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

Feb 13, 2026, 4:30 PM EST - 2 months ago

Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program

Feb 5, 2026, 9:15 AM EST - 2 months ago

Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program

Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

Jan 29, 2026, 9:15 AM EST - 3 months ago

Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

Longeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026

Dec 29, 2025, 9:15 AM EST - 4 months ago

Longeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026

Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging

Dec 2, 2025, 9:15 AM EST - 5 months ago

Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging

Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer's Disease Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)

Dec 1, 2025, 12:00 PM EST - 5 months ago

Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer's Disease Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)

Longeveron Laromestrocel Data in Alzheimer's Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)

Nov 19, 2025, 9:15 AM EST - 5 months ago

Longeveron Laromestrocel Data in Alzheimer's Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025)

Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy

Nov 12, 2025, 9:05 AM EST - 5 months ago

Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy

Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect

Oct 27, 2025, 9:15 AM EDT - 6 months ago

Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR's BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect

Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Oct 6, 2025, 9:15 AM EDT - 7 months ago

Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Longeveron® to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Sep 22, 2025, 9:15 AM EDT - 7 months ago

Longeveron® to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Longeveron® Announces Key Leadership Updates

Sep 3, 2025, 4:05 PM EDT - 8 months ago

Longeveron® Announces Key Leadership Updates

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 20, 2025, 9:15 AM EDT - 8 months ago

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 13, 2025, 4:05 PM EDT - 9 months ago

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

Aug 11, 2025, 4:15 PM EDT - 9 months ago

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

Longeveron Announces Up To $17.5 Million Public Offering

Aug 8, 2025, 1:28 PM EDT - 9 months ago

Longeveron Announces Up To $17.5 Million Public Offering

Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

Aug 5, 2025, 9:15 AM EDT - 9 months ago

Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

Jul 21, 2025, 9:15 AM EDT - 9 months ago

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

Jul 8, 2025, 9:15 AM EDT - 10 months ago

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

Longeveron® Appoints Than Powell as Chief Business Officer

Jun 26, 2025, 9:05 AM EDT - 10 months ago

Longeveron® Appoints Than Powell as Chief Business Officer

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Jun 24, 2025, 6:30 AM EDT - 10 months ago

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 9, 2025, 9:15 AM EDT - 11 months ago

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Longeveron® to Attend BIO International Convention 2025

May 20, 2025, 9:15 AM EDT - 1 year ago

Longeveron® to Attend BIO International Convention 2025

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

May 12, 2025, 7:15 AM EDT - 1 year ago

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 4:05 PM EDT - 1 year ago

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

May 2, 2025, 8:30 AM EDT - 1 year ago

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's Disease

Longeveron® to Present at the 37th Annual Roth Conference

Mar 5, 2025, 9:25 AM EST - 1 year ago

Longeveron® to Present at the 37th Annual Roth Conference

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

Feb 28, 2025, 4:04 PM EST - 1 year ago

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

Feb 18, 2025, 9:25 AM EST - 1 year ago

Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

Longeveron to Present at Biotech Showcase 2025

Dec 18, 2024, 9:10 AM EST - 1 year ago

Longeveron to Present at Biotech Showcase 2025

Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024

Dec 2, 2024, 9:05 AM EST - 1 year ago

Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024

Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

Nov 11, 2024, 9:05 AM EST - 1 year ago

Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Longeveron® Presents Lomecel-B™ Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Oct 29, 2024, 10:00 AM EDT - 1 year ago

Longeveron® Presents Lomecel-B™ Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Oct 27, 2024, 3:10 PM EDT - 1 year ago

Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Longeveron® Lomecel-B™ Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Oct 14, 2024, 9:05 AM EDT - 1 year ago

Longeveron® Lomecel-B™ Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)

Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Oct 9, 2024, 9:05 AM EDT - 1 year ago

Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting

Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day

Oct 7, 2024, 9:05 AM EDT - 1 year ago

Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day

Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Oct 2, 2024, 9:05 AM EDT - 1 year ago

Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Sep 26, 2024, 9:05 AM EDT - 1 year ago

Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa

Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 26, 2024, 4:05 PM EDT - 1 year ago

Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer's Disease at the Alzheimer's Association International Conference® (AAIC)

Jul 28, 2024, 4:51 PM EDT - 1 year ago

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer's Disease at the Alzheimer's Association International Conference® (AAIC)

Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jul 19, 2024, 4:05 PM EDT - 1 year ago

Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

smojo2
smojo2 Apr. 23 at 2:11 PM
$LGVN Man i was excited for to have a golden cross but its been bad. Need some volume and buying
0 · Reply
Carolinastokes1
Carolinastokes1 Apr. 21 at 4:15 PM
$LGVN has anyone heard they are releasing 30 million shares?
0 · Reply
tommiemac
tommiemac Apr. 21 at 4:10 PM
$LGVN bought in here like what this company is doing
0 · Reply
tommiemac
tommiemac Apr. 21 at 4:06 PM
$LGVN what does it take to buy on Webull
0 · Reply
Kingdaley
Kingdaley Apr. 20 at 6:46 PM
$LGVN going up from here
0 · Reply
Kingdaley
Kingdaley Apr. 20 at 6:43 PM
$LGVN golden cross baby
0 · Reply
seven7s
seven7s Apr. 16 at 3:59 AM
$LGVN $10K putting in this tmrw
0 · Reply
janlukas
janlukas Apr. 15 at 9:20 PM
$LGVN 10 days above a dollar, almost there, and then a crazy rush to $100. We have a unique pipeline.
0 · Reply
DoiRTN
DoiRTN Apr. 15 at 2:08 PM
$LGVN Why so silent?
0 · Reply
milk25
milk25 Apr. 14 at 11:35 PM
$LGVN are we at nasdaq compliance now
1 · Reply
stoxx0007
stoxx0007 Apr. 13 at 1:41 PM
$LGVN = who is loading the boat here today?? My boat is FULL of LGVN!! 💯💥
0 · Reply
Pillows85
Pillows85 Apr. 12 at 5:25 PM
$LGVN let’s go!!!
0 · Reply
focafoca99
focafoca99 Apr. 11 at 9:12 PM
$LGVN restored executive and board pay after closing its financing and also approved new RSU grants for senior leadership.
0 · Reply
Italianjobyolly
Italianjobyolly Apr. 10 at 8:16 PM
$LGVN offering
0 · Reply
luminouslumens
luminouslumens Apr. 10 at 6:30 PM
$LGVN
1 · Reply
stoxx0007
stoxx0007 Apr. 10 at 6:23 PM
$LGVN Bring that volume & the price will follow it UP!
0 · Reply
stoxx0007
stoxx0007 Apr. 10 at 10:33 AM
$LGVN = analysts have a price target of $7.00 LGVN. So it appears it is EXTREMELY Undervalued at $1.00 💯💥
0 · Reply
luminouslumens
luminouslumens Apr. 9 at 12:41 PM
$CMND $TJGC $COOK $PTLE $KPRX $LGVN Top multi day runners to keep an eye on
0 · Reply
stoxx0007
stoxx0007 Apr. 9 at 9:10 AM
$LGVN = seems like theres some accumulation taking place here. 💥
0 · Reply
Huskersnsaints
Huskersnsaints Apr. 8 at 5:21 PM
$LGVN this is one stock that just won't run all this positive news and you might get .05-.10 but it always retraces back then it creeps up .01-.02 a day which is ok but as far as a spike on never it just never seems to happen!!!!! VERY ODD FOR THESE MARKETS
0 · Reply
janlukas
janlukas Apr. 8 at 3:00 PM
$LGVN I don't care if it goes down, this is great news, along with its pipeline. Lgvn between $75 and $100.
2 · Reply
Stock_Catcher
Stock_Catcher Apr. 8 at 1:15 PM
$LGVN Longeveron Granted Chinese Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
0 · Reply